SweetValueLab
Write for us

Ventas, Inc. — Wall Street Analyst Estimates & Price Targets

VTR
NYSEReal EstateREIT - Healthcare FacilitiesCIK 0000740260ventasreit.comAbout VTR
Last close · Oct 16, 202685.86+1.00 (+1.18%)
Market cap$44.0B

7 firms' latest targets, last 90 days: median $102.00 ($91.00–$107.00), 19% above the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker
$70.0$80.0$90.0$100$110NovJan 2026MarMayJulSep2025-10-21 · Wells Fargo: $80.02025-10-31 · Cantor Fitzgerald: $85.02025-11-25 · Wells Fargo: $88.02025-12-04 · KeyBanc: $85.02025-12-15 · Jefferies: $93.02026-01-05 · Cantor Fitzgerald: $93.02026-01-09 · Goldman Sachs: $94.02026-02-09 · Goldman Sachs: $1002026-02-09 · UBS: $85.02026-02-10 · Argus Research: $88.02026-02-10 · RBC Capital: $91.02026-02-13 · Morgan Stanley: $90.02026-04-29 · Evercore ISI: $95.02026-05-04 · BMO Capital: $1002026-05-04 · RBC Capital: $98.02026-05-04 · UBS: $93.02026-05-07 · KeyBanc: $95.02026-05-12 · Jefferies: $1002026-05-19 · Goldman Sachs: $1102026-05-21 · Scotiabank: $95.02026-05-22 · Mizuho Securities: $98.02026-06-16 · Raymond James: $94.02026-06-16 · Deutsche Bank: $1002026-06-18 · Scotiabank: $88.02026-07-07 · Barclays: $99.02026-07-22 · Mizuho Securities: $1042026-07-31 · Cantor Fitzgerald: $1022026-08-11 · BMO Capital: $1072026-08-31 · Barclays: $1022026-09-01 · Wells Fargo: $1042026-09-15 · Jefferies: $1022026-09-21 · Evercore ISI: $1002026-10-13 · Barclays: $91.0
$70.0$80.0$90.0$100$110NovFebMayAug

Each firm's latest target

last 90 days · 7 firms
DateFirmTargetPreviousChangeVs price thenVs price now
2026-10-13Barclays$91.00$102.00▼ 11%+9%+6%
2026-09-21Evercore ISI$100.00$95.00▲ 5%+15%+16%
2026-09-15Jefferies$102.00$100.00▲ 2%+14%+19%
2026-09-01Wells Fargo$104.00$88.00▲ 18%+14%+21%
2026-08-11BMO Capital$107.00$100.00▲ 7%+16%+25%
2026-07-31Cantor Fitzgerald$102.00$93.00▲ 10%+11%+19%
2026-07-22Mizuho Securities$104.00$98.00▲ 6%+7%+21%

Consensus estimates

revenue and EPS by fiscal year · reported years marked
FYRevenueYoYEPSYoYRevenue rangeEPS rangeAnalysts
2022reported$4.1B+8%-$0.12-192%est. $4.1B+1%est. -$0.013
2023reported$4.5B+9%-$0.10—est. $4.5B+1%est. -$0.049
2024reported$4.9B+9%$0.19—est. $4.9B+1%est. $0.106
2025reported$5.8B+18%$0.54+184%est. $5.7B+2%est. $0.492
2026$6.9B+19%$0.59+22%$6.8B–$7.0B$0.59–$0.605
2027$7.7B+10%$0.95+60%$7.5B–$7.8B$0.90–$0.983
2028$8.5B+10%$1.27+34%$8.3B–$8.5B$0.94–$1.503
2029$9.1B+8%$1.94+53%$8.9B–$9.3B$1.87–$1.981
A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.